Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

295

Enrollment

INDUSTRY

Sponsor class

Stopped The study has a double-blind period and an open-label period. The study did not meet its primary endpoints after the primary LSLV and the decision was taken to terminate the study early.

Conditions

Nasal Polyposis
Eosinophilic Chronic Rhinosinusitis

Interventions

BIOLOGICAL: Benralizumab 30 mg
BIOLOGICAL: Matched placebo

Sponsor

AstraZeneca